All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, randomized controlled clinical intervention study to
evaluate the efficacy and safety of all-trans retinoic acid (ATRA) in treating patients with
recurrent metastatic adenoid cystic carcinoma of the head and neck.
Phase:
Phase 2
Details
Lead Sponsor:
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University